Maze Therapeutics initiated with a Buy at H.C. Wainwright

H.C. Wainwright initiated coverage of Maze Therapeutics (MAZE) with a Buy rating and $34 price target The company’s MZE782, a first-in-class SLC6A19 small molecule inhibitor for chronic kidney disease, could be “game changer” for the stock, with the Phase 1 data reading out in Q3, the analyst tells investors in a research note. The firm says Maze’s Compass platform transforms human genetic variant information into mechanism-based drug programs.